Novo Nordisk shares plunge after Wegovy-maker cuts full-year guidance
The Novo Nordisk logo displayed on a screen in the background is seen with medical bottles and a syringe.
Nurphoto | Nurphoto | Getty Images
Danish drug giant Novo Nordisk reduces full -year sales and profit guidance on Tuesday, indicating weaker growth expectations for the wegovy obesity drug in the US key market.
Stocks fell at 12:10 at London shortly after the announcement (07:12 meat).
The company said that the lower appearance was directed by the second half -sales growth forecasts for the treatment of wegovy weight loss medication and Özempic diabetes.
“The sales view for Wegovy in the United States reflects the continuous use of compound GLP-1s, the slow market expansion and competition than expected.”
This is an developing story. Please check again for updates.
